Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Advanced Micro Devices (AMD) stock is on the rise after Piper Sandler analysts lifted their price target for the stock to $140. Sarepta Therapeutics (SRPT) stock plunges after the company reported a second patient death from its experimental gene therapy trial.

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys.

Sarepta Therapeutics, Inc. stock fell after an ELEVIDYS-related death. However, click for why strong SRTP revenue growth and reset expectations lead to a Buy rating.

Sarepta Therapeutics falls sharply after suspending shipments of Elevidys for infusions in non-ambulatory patients because of the death of a second patient from acute liver failure.

Shares of Sarepta Therapeutics, Inc. (SRPT) traded 46% lower on Monday morning after multiple analysts downgraded the stock following the death of a second patient during their treatment with the firm’s gene therapy Elevidys.

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an analysis of SRPT stock now.